Cargando…

Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis

Vitamin D modulates bisphosphonate (BP) efficacy, but its contribution to bone mineral density (BMD) after BP discontinuation is not known. To address this topic, we performed a retrospective analysis of postmenopausal women exposed to alendronate (ALN) to treat osteoporosis who regularly continued...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catalano, Antonino, Bellone, Federica, Santoro, Domenico, Schwarz, Peter, Gaudio, Agostino, Basile, Giorgio, Sottile, Maria Carmela, Stoian, Sabrina Atena, Corica, Francesco, Morabito, Nunziata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226654/ https://www.ncbi.nlm.nih.gov/pubmed/34072655 http://dx.doi.org/10.3390/nu13061878

Ejemplares similares

Early Changes of VEGF Levels After Zoledronic Acid in Women With Postmenopausal Osteoporosis: A Potential Role of Vitamin D
por: Bellone, Federica, et al.
Publicado: (2021)

Anxiety Levels Predict Bone Mineral Density in Postmenopausal Women Undergoing Oral Bisphosphonates: A Two-Year Follow-Up
por: Martino, Gabriella, et al.
Publicado: (2021)

Sclerostin and Vascular Pathophysiology
por: Catalano, Antonino, et al.
Publicado: (2020)

Trabecular bone score and phalangeal quantitative ultrasound are associated with muscle strength and fracture risk in hemodialysis patients
por: Catalano, Antonino, et al.
Publicado: (2022)

Interrelations between clinical-psychological features and bone mineral density changes in post-menopausal women undergoing anti-osteoporotic treatment: a two-year follow-up
por: Martino, Gabriella, et al.
Publicado: (2023)

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer
por: Martino, Gabriella, et al.
Publicado: (2020)

SUN-343 Prevalence and Incidence of Hypomagnesemia and Hypermagnesemia in Medical Settings
por: Catalano, Antonino, et al.
Publicado: (2020)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

Pathogenesis of Thalassemia Major-associated Osteoporosis: A Review with Insights from Clinical Experience
por: Gaudio, Agostino, et al.
Publicado: (2019)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Knowledge and compliance towards alendronate therapy among postmenopausal women with osteoporosis in Palestine
por: Radwan, Asma, et al.
Publicado: (2022)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Cost-effectiveness of teriparatide compared with alendronate and risedronate for the treatment of postmenopausal osteoporosis patients in Iran
por: Ebadi Fard Azar, Amir Ali, et al.
Publicado: (2017)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
por: Li, Mei, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Osteoporosis and Fragility Fractures in Type 2 Diabetes
por: Chiodini, Iacopo, et al.
Publicado: (2020)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2017)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
por: You, Ruxu, et al.
Publicado: (2020)

Mechanistic PK-PD model of alendronate treatment of postmenopausal osteoporosis predicts bone site-specific response
por: Calvo-Gallego, José L., et al.
Publicado: (2022)

Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study
por: Villagómez Vega, Alejandra, et al.
Publicado: (2023)

An unusual bilateral groin pain after COVID-19 infection in an 82-year-old man
por: Bellone, Federica, et al.
Publicado: (2023)

As Time Goes by: Anxiety Negatively Affects the Perceived Quality of Life in Patients With Type 2 Diabetes of Long Duration
por: Martino, Gabriella, et al.
Publicado: (2019)

Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis
por: Deng, Jing, et al.
Publicado: (2018)

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy
por: Hiligsmann, M., et al.
Publicado: (2021)

Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females
por: Mok, Ji Oh, et al.
Publicado: (2013)

Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
por: Iwamoto, Jun, et al.
Publicado: (2009)

Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2009)

Combination therapy of curcumin and alendronate modulates bone turnover markers and enhances bone mineral density in postmenopausal women with osteoporosis
por: Khanizadeh, Fatemeh, et al.
Publicado: (2018)

The Efficacy and Safety of a Combined Alendronate and Calcitriol Agent (Maxmarvil): A Postmarketing Surveillance Study in Korean Postmenopausal Women with Osteoporosis
por: Suh, Hee-Won, et al.
Publicado: (2012)

Treated Hypertension has No Influence on the Efficacy of Alendronate in the Therapy of Postmenopausal Osteoporosis: A Non-Randomized, Non-Blind, Controlled Prospective Study
por: Matziolis, Doerte, et al.
Publicado: (2011)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
por: Chen, Ling-Xiao, et al.
Publicado: (2015)

A critical review of brand and generic alendronate for the treatment of osteoporosis
por: Brown, Jacques P, et al.
Publicado: (2013)

Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women
por: Um, Mi Jung, et al.
Publicado: (2017)

Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
por: Kim, Yeesuk, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gav3504k6rert83ije9pb5b6pl